Cargando…
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete pathologic response has been shown to be an appr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504845/ https://www.ncbi.nlm.nih.gov/pubmed/37720499 http://dx.doi.org/10.1177/17588359231198446 |